HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: M700170-JLR200v1 48/11/2411    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Buono, C. Articles by Kruth, H. S. Search for Related Content PubMed PubMed Citation Articles by Buono, C. Articles by Kruth, H. S. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol. 48, 2411-2418, November 2007
Copyright © 2007 by American Society for Biochemistry and Molecular Biology

Liver X receptors inhibit human monocyte-derived macrophage foam cell formation by inhibiting fluid-phase pinocytosis of LDL

Chiara Buono^*, Yifu Li^*, Stephen W. Waldo^*, and Howard S. Kruth^1,*

^* Section of Experimental Atherosclerosis, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892-1422
Howard Hughes Medical Institute, National Institutes of Health Medical Research Scholar Program, Bethesda, MD 20892-1422

Published, JLR Papers in Press, August 10, 2007.

¹ To whom correspondence should be addressed. e-mail: kruthh{at}nhlbi.nih.gov

Liver X receptors (LXRs) are ligand-activated transcription factors involved in the control of lipid metabolism and inflammation. Several studies have recently shown that LXRs promote reverse cholesterol transport and inhibit atherosclerosis. Our study investigated whether LXRs affect macrophage uptake of LDL by human monocyte-derived macrophages. We have previously shown that human monocytes differentiated into macrophages with macrophage-colony-stimulating factor (M-CSF) constitutively take up large amounts of native LDL by receptor-independent, fluid-phase pinocytosis. In the research reported here, human monocytes were differentiated to macrophages in the presence of M-CSF with or without the LXR agonists T0901317 or 22(R)-hydroxycholesterol. Then, macrophages were incubated with native ¹²⁵I-LDL to determine LDL uptake. T0901317 and 22(R)-hydroxycholesterol inhibited ¹²⁵I-LDL uptake by 68 ± 1% and 69 ± 2%, respectively, and decreased pinocytotic vacuoles in the macrophages. ¹²⁵I-BSA uptake, a measure of fluid-phase pinocytosis, and ¹²⁵I-LDL uptake were the same, and T0901317 treatment inhibited uptake of both to the same degree. T0901317 did not affect receptor-mediated uptake of acetylated LDL, showing that the LXR effect is specific for fluid-phase pinocytosis of lipoproteins. Our results show that LXRs downregulate macrophage pinocytosis of LDL. The findings reveal an additional new mechanism by which LXR agonists may inhibit macrophage cholesterol accumulation and atherosclerosis, namely, by inhibiting macrophage uptake of LDL.

Supplementary key words atherosclerosis • cholesterol • endocytosis

Abbreviations: DPBS, Dulbecco's phosphate-buffered saline; LXR, liver X receptor; M-CSF, macrophage-colony-stimulating factor; PPAR, peroxisome proliferator-activated receptor

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. W. Waldo, Y. Li, C. Buono, B. Zhao, E. M. Billings, J. Chang, and H. S. Kruth Heterogeneity of Human Macrophages in Culture and in Atherosclerotic Plaques Am. J. Pathol., April 1, 2008; 172(4): 1112 - 1126. [Abstract] [Full Text] [PDF]